Oruka Therapeutics, Inc. (NASDAQ:ORKA) Shares Sold by Point72 Asset Management L.P.

Point72 Asset Management L.P. lessened its stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) by 25.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 360,732 shares of the company's stock after selling 121,598 shares during the period. Point72 Asset Management L.P. owned about 1.03% of Oruka Therapeutics worth $6,995,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. FMR LLC boosted its position in Oruka Therapeutics by 17.7% in the 4th quarter. FMR LLC now owns 5,512,300 shares of the company's stock worth $106,883,000 after purchasing an additional 830,000 shares in the last quarter. Fairmount Funds Management LLC boosted its position in Oruka Therapeutics by 5.0% in the 4th quarter. Fairmount Funds Management LLC now owns 3,371,922 shares of the company's stock worth $65,382,000 after purchasing an additional 160,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Oruka Therapeutics by 4,161.2% in the 4th quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock worth $31,231,000 after purchasing an additional 1,572,853 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Oruka Therapeutics by 374.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company's stock worth $25,730,000 after purchasing an additional 1,047,245 shares in the last quarter. Finally, Braidwell LP boosted its position in Oruka Therapeutics by 122.5% in the 4th quarter. Braidwell LP now owns 1,147,676 shares of the company's stock worth $22,253,000 after purchasing an additional 631,950 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company's stock.

Oruka Therapeutics Trading Down 2.1%

ORKA stock traded down $0.24 during midday trading on Friday, reaching $10.95. The stock had a trading volume of 135,502 shares, compared to its average volume of 225,915. The company's fifty day simple moving average is $9.79 and its 200 day simple moving average is $14.12. The company has a market cap of $409.98 million, a price-to-earnings ratio of -1.75 and a beta of 0.25. Oruka Therapeutics, Inc. has a 52-week low of $5.49 and a 52-week high of $31.13.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. Sell-side analysts predict that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Wolfe Research assumed coverage on Oruka Therapeutics in a research report on Tuesday, February 4th. They issued an "outperform" rating and a $20.00 price objective on the stock. BTIG Research started coverage on Oruka Therapeutics in a research report on Thursday. They set a "buy" rating on the stock. Wedbush reiterated an "outperform" rating and set a $40.00 target price on shares of Oruka Therapeutics in a research report on Thursday, May 15th. HC Wainwright reiterated a "buy" rating and set a $45.00 target price on shares of Oruka Therapeutics in a research report on Friday, February 7th. Finally, Wall Street Zen upgraded Oruka Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $40.38.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.